Relationship between expression of ERCC1 and drug therapeutic effect of cisplatin chemotherapy in advanced non- small cell lung cancer
AIM: To investigate the correlation between the expression of ERCC1 and therapeutic effect based on cisplatin chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Eighty-one stage Ⅲ B and Ⅳ NSCLC patients were enrolled in the study. The patients were randomly assigned in a 1:2 ratio to control group or ERCC1 genotypic group. ERCC1 genotypic group was further divided into ERCC1 negative group or ERCC1 positive group according to the immuno-histochemical staining of samples. The patients in control group and ERCC1 negative group received paclitaxel plus cisplatin chemotherapy while the patients in ERCC1 positive group received paclitaxel plus gemcitabine chemotherapy. The data of therapeutical effect and survival time were collected and analyzed. RESULTS : Of the remaining 79 patients, the overall response rate (CR + PR) in control group was 30.8% (8/26), obviously lower than those in ERCC1 genotypic group (54.7% , 29/53) and in ERCC1 negative group (60.7% , 17/28) (P =0.045 and P =0. 027 respectively). However, there was no remarkable difference between the three groups in the overall survival ( OS) and progression-free survival (PFS), (P=0.186 and P=0.245 respectively). CONCLUSION: The expression of ERCC1 in NSCLC samples may be considered a therapeutic effect biomarker of chemotherapy based on cisplatin. Selection of individualized therapy based on ERCC1 expression may improve the response rate of NSCLC patients.
carcinomanon-small-cell lung/ drug therapyERCC1cisplatintreatment outcome
NETL
NSTL
万方数据
维普
